Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practitioners in interpreting GastroPanel test results; and GP Reader NT for the quantitative determination of various analytes in human samples. It also provides BIOHIT active B12 (HoloTC) test, BIOHIT total 25OH vitamin D test, and BIOHIT Calprotectin; BIOHIT ColonView quick test for detection of fecal occult blood (FOB) in stool samples; BIOHIT Celiac quick test, a qualitative in vitro immunochromatographic test aiding in diagnosis of celiac disease; BIOHIT H. pylori UFT300 and H.pylori tests for the diagnosis of H,pylori infection; lactose intolerance quick test kit; and Gluten Immunogenic Peptides test. In addition, it offers Acetium acetaldehyde binding products, such as the Acetium lozenge to help quit smoking and Acetium capsule for the protection of the stomach. Further, the company provides monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. Additionally, it offers BIOHIT FAEX sample system for the collection and handling of stool samples. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.…
Vallourec sees Q4 EBITDA below expectations as Middle East disruption hits margins
Biohit (HEL: BIOBV) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 47 employees.
The shares were at 2.070 EUR on 20 November 2026, down 33.2% over 52 weeks. Its 52-week range is 2.000 EUR to 3.780 EUR: the price is 45.2% below the high and 3.5% above the low.
At a market capitalisation of 31.48M EUR, it trades at 10.3 times trailing earnings and 12.2 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 59% for BIOBV.
Biohit reports return on equity of 18.3%, an operating margin of 20.8% and revenue up 5.4% year over year.
It holds more cash than debt, a net cash position of 1.50M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 2.800 EUR is 35.3% above the current price.